Pfizer’s nasal spray, ZAVZPRET, has gained approval by the FDA

Pfizer’s nasal spray, ZAVZPRET™, which treats migraines, has gained approval from the FDA. It is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist in the form of nasal spray as a short-term treatment for migraines for adults with or without aura. Migraines affect 40 million individuals in the US and the introduction of the drug offers these people an alternative to oral medication.

The Phase 3 study, presented that in relation to the Placebo, the results of ZAVZPRET determined there was a significant difference in the relief of pain from the most bothersome symptoms. These results were a pivotal part of the breakthrough, as the treatment proved to be efficient and fast acting, with relief as early as 15 minutes after the prescribed dose.

Kathleen Mullin, M.D., Associate Medical Director at New England Institute for Neurology & Headache said: “As a nasal spray with rapid drug absorption, ZAVZPRET offers an alternative treatment option for people who need pain relief or cannot take oral medications due to nausea or vomiting, so they can get back to normal function quickly.”